|
|
||||||||||
|
J Am Coll Cardiol, 1989; 13:121-131 © 1989 by the American College of Cardiology Foundation |
Department of Medicine, University of Alabama, Birmingham 35294.
The automatic implantable cardioverter-defibrillator (AICD) effectively prevents death due to ventricular tachycardia or ventricular fibrillation. Some patients who need an AICD also require cardiac pacing to treat symptomatic bradycardia, bradycardia after defibrillation, or to provide a rate floor to reduce the frequency of bradycardia-related ventricular arrhythmias. Some patients also can benefit from antitachycardia pacing. A mapping technique to implant a pacemaker and AICD sensing leads is presented. For patients with a pacemaker who later need an AICD, the left ventricle is mapped with use of the AICD rate-sensing electrodes to identify a site at which the minimal pacemaker stimulus and maximal ventricular electrogram amplitudes are recorded. An external cardioverter-defibrillator that has amplifiers similar to those in the AICD is used to monitor the rate-sensing electrogram. For patients with an implanted AICD, pacemaker implantation is undertaken by mapping the right ventricle with the pacemaker lead while the AICD is in standby mode; the AICD beep monitor is then used to determine a site where pacemaker stimulus detection by the AICD does not occur. Eight patients underwent implantation of a combined AICD-pacemaker system (four ventricular antitachycardia pacemakers, three ventricular demand pacemakers and one atrial demand pacemaker). Neither inhibition of AICD arrhythmia detection nor double counting occurred. Satisfactory AICD-pacemaker function was shown in all patients postoperatively, and no pacemaker malfunction was observed. Thus, with currently available technology, a combined AICD-pacemaker system can be implanted with satisfactory function of both devices and without adverse device-device interactions.
This article has been cited by other articles:
![]() |
Z. Goldberger, B. Elbel, C. A. McPherson, A. D. Paltiel, and R. Lampert Cost Advantage of Dual-Chamber Versus Single-Chamber Cardioverter-Defibrillator Implantation J. Am. Coll. Cardiol., September 6, 2005; 46(5): 850 - 857. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Quesada, J.ús Almendral, F. Arribas, R. Ricci, C. Wolpert, P. Adragao, E. Cobo, X. Navarro, and on behalf DATAS investigators The DATAS rationale and design: a controlled, randomized trial to assess the clinical benefit of dual chamber (DDED) defibrillator Europace, January 1, 2004; 6(2): 142 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Kuhlkamp and InSync 7272 ICD World Wide Investigators Initial experience with an implantable cardioverter-defibrillator incorporating cardiac resynchronization therapy J. Am. Coll. Cardiol., March 6, 2002; 39(5): 790 - 797. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |